Business Wire

Technology Innovation Institute Appoints Eminent Technologist Dr Ray O. Johnson as CEO

Share

Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology body in Abu Dhabi responsible for driving research and development for transformative technology outcomes, today announced the appointment of veteran technologist and entrepreneur Dr Ray O. Johnson as Chief Executive Officer. Dr Johnson will work on shaping the strategic direction of the Institute and lead the execution of its growth strategies to achieve operational excellence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005462/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr Ray O. Johnson, Chief Executive Officer, Technology Innovation Institute (Photo: AETOSWire)

Prior to joining TII, Dr Johnson was an Operating Partner at Bessemer Venture Partners, a top-tier American venture capital company that has been part of 130 IPOs in the last 50 years, and before that, he was the Corporate Senior Vice President for Engineering, Technology, and Operations and Chief Technology Officer of the Lockheed Martin Corporation.

Dr Johnson brings to his role over four decades of experience in global technology leadership, making strategic investments in disruptive technologies, and developing business strategies that resulted in several new billion-dollar lines of business. He also holds outstanding networking capabilities; he has met with leaders at the highest echelons of government, industry, and academia. He is frequently sought after as a speaker at global forums on business, strategy, innovation, and education.

Speaking on the new appointment, His Excellency Faisal Al Bannai, Secretary General of ATRC, said: “We welcome Dr Ray Johnson as the first CEO of Technology Innovation Institute. His appointment is a much anticipated one – we were keen that the person entrusted with this role should not merely be an excellent research and technology specialist, but equally, a consummate professional and industry stakeholder that is capable of ensuring the most positive outcomes for the breakthrough projects TII is currently engaged in across its seven initial dedicated research centres.

“We are confident Dr Johnson will be able to build game-changing synergies for TII as he leads it towards realising its wider goals of growing its talented global team of 375+ researchers, scientists, and engineers, and ensuring the objectives of the current workstreams are met. He will also leverage his vast network to further expand our visibility and reach across markets.”

For his part, Dr Ray O. Johnson said: “I am very excited about this new role in a region that I admire for its dedication to advanced research and development for the betterment of the UAE. Since TII’s inception in November 2020, I have followed its many announcements and achievements with great interest. As it moves into a new phase of growth, I look forward to working with the talented teams of researchers across its centres to drive competitive results and facilitate breakthrough solutions that transition to the market.”

Technology Innovation Institute (TII) is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy, and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE, reinforces the status of Abu Dhabi and the UAE as a global hub for innovation, and contributes to the broader development of the knowledge-based economy.

For information on Advanced Technology Research Council (ATRC), visit www.atrc.ae

For information on Technology Innovation Institute (TII), visit www.tii.ae

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Hanz Valbuena
hanz.valbuena@tii.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye